novo nordisk cagrisema

Novo Nordisk's next-gen obesity drug Cagrisema

Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that hammered its shares in December.

AOL · 2d

Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

The New York Times · 1d

Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

Wegovy sales double to boost Novo Nordisk's 4th quarter

CNBC on MSN · 2d

Novo Nordisk shares rise on fourth-quarter profit beat, Wegovy sales jump

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs. Net profit for the fourth quarter came in at 28.

Investopedia on MSN · 1d

Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double

Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid "intensifying competition.

Reuters on MSN · 23h

Wegovy maker Novo Nordisk says surging growth driving emissions higher

Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as it boosts production of blockbuster obesity drug Wegovy. The company is spending billions to ramp up its Wegovy output as demand soars.

10h

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From ...

pharmaphorum23h

Novo charts course ahead for CagriSema after lacklustre data

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to scale down their dosing if, for example, they experienced side effects like ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Novo Nordisk's next-gen obesity drug Cagrisema

Wegovy sales double to boost Novo Nordisk's 4th quarter

Trending now